---
schema_version: "secwatch.filing_event.v1"
accession: "0001384101-24-000064"
form_type: "8-K"
ticker: "VCYT"
cik: "0001384101"
company_name: "VERACYTE, INC."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T17:12:56.024858+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Veracyte Q1 revenue $96.8M (+17%), testing revenue +25%, net loss narrows 77%

## Summary
- Total revenue $96.8M (up 17% YoY); testing revenue $90.3M (up 25%) led by Decipher Prostate and Afirma.
- Net loss improved 77% to $1.9M ($0.02 per share) from $8.3M loss in Q1 2023.
- Non-GAAP gross margin held at 68%; non-GAAP op expenses grew 6% to $61.6M.
- Decipher Prostate received highest NCCN rating; contracted with large commercial payer covering ~30M members.
- Completed C2i Genomics acquisition for MRD testing; initiated bladder cancer MRD test; cash $209.2M.

## SEC filing metadata
- accession: 0001384101-24-000064
- form_type: 8-K
- ticker: VCYT
- cik: 0001384101
- company_name: VERACYTE, INC.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1384101/000138410124000064/0001384101-24-000064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1384101/000138410124000064/vcyt-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001384101-24-000064
- JSON: https://secwatch.observer/filing/0001384101-24-000064.json
- Plain text: https://secwatch.observer/filing/0001384101-24-000064.txt

## Key facts
- Earnings Releases
  VERACYTE, INC. reported first quarter ended March 31, 2024 results: revenue $96.8 million, net income $1.9 million, EPS $0.02.
  - Period: first quarter ended March 31, 2024
  - Revenue: $96.8 million
  - Net income: $1.9 million
  - EPS: $0.02
  - Result: reported results
  source text: EX-99.1 (EX-99.1 PRESS RELEASE 05.07.2024) --- PRESS RELEASE 05.07.2024 Document Exhibit 99.1 Veracyte Announces First Quarter 2024 Financial Results Grew total revenue to $96.8 million, an increase of 17% Grew testing revenue by 25% Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 7, 2024 --- Veracyte, Inc. (Nasdaq: VCYT) today
  evidence_url: https://www.sec.gov/Archives/edgar/data/1384101/000138410124000064/0001384101-24-000064-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.